Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals)

抗PD1/TIM3人源化双特异抗体

Report date: 2025/08/06 10:30:55

Base Information

Drug NameAnti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals)
Drug Alias Name注射用重组抗PD1/TIM3人源化双特异抗体Bis5Bis-5
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 blockersHepatitis A virus cellular receptor 2 inhibitors
TargetsProgrammed cell death protein 1Hepatitis A virus cellular receptor 2
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesL&L Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesL&L Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A